GREENFIELD, Ind. / Dec 19, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 8-10, 2024. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts on Tuesday, January 9, 2024 at 3:00 p.m. PST (6:00 PM EST).
A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
| Last Trade: | US$21.90 |
| Daily Change: | -0.09 -0.41 |
| Daily Volume: | 3,414,851 |
| Market Cap: | US$10.880B |
November 21, 2025 November 13, 2025 November 05, 2025 October 24, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load